Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
BridgeBio files $350M mixed securities shelf  17:31
07/07/20
07/07
17:31
07/07/20
17:31
BBIO

BridgeBio

$30.41 /

+0.81 (+2.74%)

 
ShowHide Related Items >><<
BBIO BridgeBio
$30.41 /

+0.81 (+2.74%)

BBIO BridgeBio
$30.41 /

+0.81 (+2.74%)

06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
BBIO BridgeBio
$30.41 /

+0.81 (+2.74%)

  • 29
    May
BBIO BridgeBio
$30.41 /

+0.81 (+2.74%)

Over a week ago
Initiation
BridgeBio initiated with a Neutral at BofA » 07:33
06/25/20
06/25
07:33
06/25/20
07:33
BBIO

BridgeBio

$32.96 /

+0.33 (+1.01%)

BofA analyst Geoff…

BofA analyst Geoff Meacham initiated coverage of BridgeBio with a Neutral rating and $38 price target. Meacham likes the diversified pipeline with AG10, a potential best-in-class TTR stabilizer, with interesting opportunities in oncology and rare disease, as well as a variety of intriguing early stage assets, though he believes these are well appreciated by the market.

ShowHide Related Items >><<
BBIO BridgeBio
$32.96 /

+0.33 (+1.01%)

BBIO BridgeBio
$32.96 /

+0.33 (+1.01%)

06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
BBIO BridgeBio
$32.96 /

+0.33 (+1.01%)

BBIO BridgeBio
$32.96 /

+0.33 (+1.01%)

Initiation
BridgeBio initiated with a Neutral at BofA » 06:11
06/25/20
06/25
06:11
06/25/20
06:11
BBIO

BridgeBio

$32.96 /

+0.33 (+1.01%)

BofA initiated coverage…

BofA initiated coverage of BridgeBio with a Neutral rating and $38 price target.

ShowHide Related Items >><<
BBIO BridgeBio
$32.96 /

+0.33 (+1.01%)

BBIO BridgeBio
$32.96 /

+0.33 (+1.01%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
BBIO BridgeBio
$32.96 /

+0.33 (+1.01%)

BBIO BridgeBio
$32.96 /

+0.33 (+1.01%)

Hot Stocks
BridgeBio appoints Brent Saunders, Randy Scott, Andrew Lo to board » 07:44
06/24/20
06/24
07:44
06/24/20
07:44
BBIO

BridgeBio

$32.63 /

-0.44 (-1.33%)

, NVTA

Invitae

$30.01 /

+3.02 (+11.19%)

BridgeBio Pharma (BBIO)…

BridgeBio Pharma (BBIO) has added three new independent directors to its board: Brent Saunders, Randy Scott, Ph.D. and Andrew Lo, Ph.D. Saunders most recently served as chairman, president and CEO of Allergan. Scott recently served as CEO and executive chairman at Invitae (NVTA), a company he co-founded to bring genetic information into routine medical practice. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of the MIT Laboratory for Financial Engineering, a principal investigator at the MIT Computer Science and Artificial Intelligence Laboratory, and an affiliated faculty member of the MIT Department of Electrical Engineering and Computer Science.

ShowHide Related Items >><<
NVTA Invitae
$30.01 /

+3.02 (+11.19%)

BBIO BridgeBio
$32.63 /

-0.44 (-1.33%)

BBIO BridgeBio
$32.63 /

-0.44 (-1.33%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
NVTA Invitae
$30.01 /

+3.02 (+11.19%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
05/06/20 SVB Leerink
Invitae price target raised to $25 from $20 at SVB Leerink
04/02/20 Oppenheimer
Invitae price target lowered to $25 from $32 at Oppenheimer
02/20/20 Cowen
Invitae price target raised to $30 from $20 at Cowen
NVTA Invitae
$30.01 /

+3.02 (+11.19%)

BBIO BridgeBio
$32.63 /

-0.44 (-1.33%)

NVTA Invitae
$30.01 /

+3.02 (+11.19%)

NVTA Invitae
$30.01 /

+3.02 (+11.19%)

BBIO BridgeBio
$32.63 /

-0.44 (-1.33%)

Conference/Events
BMO Capital to hold a virtual conference » 08:41
06/23/20
06/23
08:41
06/23/20
08:41
ANTM

Anthem

$265.10 /

-1.41 (-0.53%)

, IMUX

Immunic

$14.17 /

+0.36 (+2.61%)

, SRRK

Scholar Rock

$19.09 /

+0.27 (+1.43%)

, EHC

Encompass Health

$63.73 /

-0.48 (-0.75%)

, FLXN

Flexion

$12.71 /

-0.02 (-0.16%)

, REGN

Regeneron

$627.91 /

-15.055 (-2.34%)

, SLGL

Sol-Gel Technologies

$8.44 /

+0.2 (+2.43%)

, MORF

Morphic Holding

$29.62 /

+2.45 (+9.02%)

, MNK

Mallinckrodt

$2.91 /

+0.355 (+13.89%)

, ETTX

Entasis Therapeutics

$2.99 /

-0.035 (-1.16%)

, AGTC

Applied Genetic

$6.39 /

+0.255 (+4.16%)

, HZNP

Horizon Therapeutics

$52.52 /

+2.545 (+5.09%)

, BBIO

BridgeBio

$33.07 /

+1.06 (+3.31%)

, AQST

Aquestive Therapeutics

$5.42 /

+0.01 (+0.18%)

, BTAI

BioXcel Therapeutics

$56.96 /

+4.27 (+8.10%)

, CNC

Centene

$63.09 /

-1.08 (-1.68%)

, LNTH

Lantheus

$13.99 /

-0.58 (-3.98%)

, SDGR

Schrodinger

$75.65 /

+0.49 (+0.65%)

, SCPH

scPharmaceuticals

$7.55 /

+0.35 (+4.86%)

, PHAT

Phathom Pharmaceuticals

$45.36 /

-0.635 (-1.38%)

, HUM

Humana

$379.31 /

-1.3 (-0.34%)

, HARP

Harpoon Therapeutics

$18.18 /

-0.02 (-0.11%)

Prescriptions for Success…

Prescriptions for Success Healthcare Virtual Conference will be held on June 23 at 9 am. Webcast Link

ShowHide Related Items >><<
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

MORF Morphic Holding
$29.62 /

+2.45 (+9.02%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

06/05/20 Goldman Sachs
Anthem initiated with a Neutral at Goldman Sachs
06/01/20 Piper Sandler
Kentucky contract positive for Molina, negative for Anthem, says Piper Sandler
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/21/20 SunTrust
SunTrust raises price targets across select Healthcare Services names
IMUX Immunic
$14.17 /

+0.36 (+2.61%)

06/04/20 Wedbush
Wedbush starts Immunic at Outperform with $59 price target
06/04/20 Wedbush
Immunic initiated with an Outperform at Wedbush
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

05/29/20 Mizuho
Encompass Health price target lowered to $87 from $90 at Mizuho
04/20/20 BMO Capital
Encompass Health price target raised to $83 from $66 at BMO Capital
03/06/20 Deutsche Bank
Encompass Health price target raised to $83 from $73 at Deutsche Bank
03/05/20 BMO Capital
Encompass Health price target raised to $95 from $88 at BMO Capital
FLXN Flexion
$12.71 /

-0.02 (-0.16%)

05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Flexion initiated with a Buy at Guggenheim
05/08/20 Needham
Flexion price target lowered to $20 from $30 at Needham
04/02/20 Benchmark
Flexion price target lowered to $17 from $25 at Benchmark
REGN Regeneron
$627.91 /

-15.055 (-2.34%)

06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/02/20 Cantor Fitzgerald
Regeneron price target raised to $624 from $400 at Cantor Fitzgerald
SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
MORF Morphic Holding
$29.62 /

+2.45 (+9.02%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
ETTX Entasis Therapeutics
$2.99 /

-0.035 (-1.16%)

05/08/20 BMO Capital
Entasis Therapeutics price target lowered to $5 from $15 at BMO Capital
04/14/20 H.C. Wainwright
Entasis Therapeutics price target lowered to $5 from $18 at H.C. Wainwright
08/19/19 H.C. Wainwright
Entasis Therapeutics initiated with a Buy at H.C. Wainwright
AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

06/23/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
06/22/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
02/12/20 Roth Capital
Applied Genetic in position to execute after cash raise, says Roth Capital
01/28/20
Fly Intel: Top five analyst initiations
HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

06/10/20 Mizuho
Mizuho doctor survey shows preference for SEL-212 over Krystexxa
05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
CNC Centene
$63.09 /

-1.08 (-1.68%)

04/29/20 Oppenheimer
Centene price target raised to $90 from $83 at Oppenheimer
04/29/20 Piper Sandler
Centene selloff yesterday a buying opportunity, says Piper Sandler
04/09/20 Jefferies
Anthem downgraded to Hold on Commercial Risk at Jefferies
LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

06/16/20 CJS Securities
Lantheus upgraded to Outperform from Market Perform at CJS Securities
10/02/19 Credit Suisse
Lantheus deal for Progenics has 'some strategic merit,' says Credit Suisse
08/16/19
Lantheus upgraded to Outperform from Market Perform at CJS Securities
SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

06/02/20 BMO Capital
Schrodinger price target raised to $85 from $67 at BMO Capital
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Jefferies
Schrodinger initiated with a Hold at Jefferies
03/02/20 Morgan Stanley
Schrodinger initiated with an Equal Weight at Morgan Stanley
SCPH scPharmaceuticals
$7.55 /

+0.35 (+4.86%)

05/13/20 SVB Leerink
scPharmaceuticals price target raised to $12 from $7 at SVB Leerink
05/13/20 H.C. Wainwright
scPharmaceuticals price target raised to $15 from $13 at H.C. Wainwright
10/15/19 H.C. Wainwright
scPharmaceuticals initiated with a Buy at H.C. Wainwright
PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
HUM Humana
$379.31 /

-1.3 (-0.34%)

06/18/20 Deutsche Bank
Humana price target lowered to $397 from $421 at Deutsche Bank
06/17/20 Cantor Fitzgerald
Humana price target raised to $410 from $405 at Cantor Fitzgerald
06/16/20 Cowen
Humana downgraded to Market Perform on valuation at Cowen
06/16/20 Cowen
Humana downgraded to Market Perform from Outperform at Cowen
HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

06/01/20 Wedbush
Harpoon Therapeutics price target raised to $36 from $26 at Wedbush
06/01/20 Piper Sandler
Harpoon initial data for HPN424 'highly encouraging,' says Piper Sandler
05/29/20 Roth Capital
Harpoon Therapeutics price target raised to $31 from $25 at Roth Capital
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

SCPH scPharmaceuticals
$7.55 /

+0.35 (+4.86%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

ETTX Entasis Therapeutics
$2.99 /

-0.035 (-1.16%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

Hot Stocks
BridgeBio enters collaboration agreement with Johns Hopkins University » 07:42
06/18/20
06/18
07:42
06/18/20
07:42
BBIO

BridgeBio

$31.66 /

-0.07 (-0.22%)

BridgeBio Pharma…

BridgeBio Pharma announced that it has entered into a collaboration agreement with Johns Hopkins University to support the translation of academic innovations in genetically driven diseases with a goal of clinical development and potential commercialization to reach patients in need. BridgeBio has a deep interest in understanding where great science is occurring and determining how it can support translating academic findings into treatments for patients, including by helping advance the important discoveries in genetic drivers of specific diseases made at Johns Hopkins. The company is focused on building relationships with academic partners to smooth and speed up the transition from the lab to the patient. BridgeBio will focus on opportunities to support the incredible, early-discovery research around genetically validated targets underway at Johns Hopkins. Where possible, BridgeBio will invest heavily in programs to accelerate promising genetic-disease therapies to the clinic, from gene therapy to small molecule. It will lend its expertise to science designed to help develop a promising molecule or approach into a viable preclinical program, including medicinal chemistry for small-molecule hit optimization, strategies to modify or formulate a potential biologic therapy or approaches for testing non-optimized viral vectors. Additionally, BridgeBio may conduct proof-of-concept studies for lead therapeutic compounds in relevant mammalian models.

ShowHide Related Items >><<
BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

Hot Stocks
BridgeBio, University of Florida announce strategic collaboration » 07:41
06/18/20
06/18
07:41
06/18/20
07:41
BBIO

BridgeBio

$31.66 /

-0.07 (-0.22%)

BridgeBio Pharma entered…

BridgeBio Pharma entered into a strategic collaboration with the University of Florida to translate research in genetically driven disease towards clinical development and potential commercialization. The partnership combines University of Florida's prowess in studying genetically driven disease, including its capabilities in gene therapy, with BridgeBio's expertise in efficiently advancing therapeutics from the academic laboratory through preclinical studies and into human testing. BridgeBio believes that, too often, promising research in academia sits on the shelf without partners to move it forward. The company's mission is to bring as much of that research forward as possible, by focusing on establishing partnerships with leading institutions in the hopes of translating research into life-saving therapies. BridgeBio will provide sponsorship to select research programs around diseases with a genetic basis, including gene therapies and large and small molecules. The company will provide guidance for sponsored programs around medicinal chemistry for small-molecule hit optimization, strategies to modify or formulate a potential biologic therapy or approaches for testing non-optimized viral vectors. BridgeBio may conduct proof-of-concept studies for lead therapeutic compounds in relevant mammalian models. BridgeBio seeks to revolutionize partnerships between drug development companies and biomedical research institutions by moving away from one-off interactions and building long-term partnerships based on trust, engagement, science and respect. The company is committed to acting responsibly towards the academic investigators who are on the front lines of understanding the mechanisms of genetically driven diseases and have great insights into how these diseases may be treated.

ShowHide Related Items >><<
BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

Conference/Events
Raymond James a virtual conference » 04:55
06/18/20
06/18
04:55
06/18/20
04:55
XNCR

Xencor

$29.85 /

-0.32 (-1.06%)

, BBIO

BridgeBio

$31.66 /

-0.07 (-0.22%)

, MGTA

Magenta Therapeutics

$9.39 /

+0.175 (+1.90%)

, OCUL

Ocular Therapeutix

$8.68 /

-0.15 (-1.70%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 15-18.

ShowHide Related Items >><<
XNCR Xencor
$29.85 /

-0.32 (-1.06%)

OCUL Ocular Therapeutix
$8.68 /

-0.15 (-1.70%)

MGTA Magenta Therapeutics
$9.39 /

+0.175 (+1.90%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

XNCR Xencor
$29.85 /

-0.32 (-1.06%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
MGTA Magenta Therapeutics
$9.39 /

+0.175 (+1.90%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
OCUL Ocular Therapeutix
$8.68 /

-0.15 (-1.70%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
XNCR Xencor
$29.85 /

-0.32 (-1.06%)

OCUL Ocular Therapeutix
$8.68 /

-0.15 (-1.70%)

MGTA Magenta Therapeutics
$9.39 /

+0.175 (+1.90%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

XNCR Xencor
$29.85 /

-0.32 (-1.06%)

OCUL Ocular Therapeutix
$8.68 /

-0.15 (-1.70%)

MGTA Magenta Therapeutics
$9.39 /

+0.175 (+1.90%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

Conference/Events
Raymond James a virtual conference » 04:55
06/17/20
06/17
04:55
06/17/20
04:55
XNCR

Xencor

$30.17 /

+0.09 (+0.30%)

, BBIO

BridgeBio

$31.73 /

+0.62 (+1.99%)

, MGTA

Magenta Therapeutics

$9.22 /

-0.005 (-0.05%)

, OCUL

Ocular Therapeutix

$8.83 /

+0.57 (+6.90%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 15-18.

ShowHide Related Items >><<
XNCR Xencor
$30.17 /

+0.09 (+0.30%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

MGTA Magenta Therapeutics
$9.22 /

-0.005 (-0.05%)

BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

XNCR Xencor
$30.17 /

+0.09 (+0.30%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
MGTA Magenta Therapeutics
$9.22 /

-0.005 (-0.05%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
XNCR Xencor
$30.17 /

+0.09 (+0.30%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

MGTA Magenta Therapeutics
$9.22 /

-0.005 (-0.05%)

BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

XNCR Xencor
$30.17 /

+0.09 (+0.30%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

MGTA Magenta Therapeutics
$9.22 /

-0.005 (-0.05%)

BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

Conference/Events
Raymond James a virtual conference » 04:55
06/16/20
06/16
04:55
06/16/20
04:55
XNCR

Xencor

$30.08 /

+1.64 (+5.77%)

, BBIO

BridgeBio

$31.11 /

+2.4 (+8.36%)

, MGTA

Magenta Therapeutics

$9.22 /

+0.14 (+1.54%)

, OCUL

Ocular Therapeutix

$8.26 /

+0.8 (+10.72%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 15-18.

ShowHide Related Items >><<
XNCR Xencor
$30.08 /

+1.64 (+5.77%)

OCUL Ocular Therapeutix
$8.26 /

+0.8 (+10.72%)

MGTA Magenta Therapeutics
$9.22 /

+0.14 (+1.54%)

BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

XNCR Xencor
$30.08 /

+1.64 (+5.77%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
MGTA Magenta Therapeutics
$9.22 /

+0.14 (+1.54%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
OCUL Ocular Therapeutix
$8.26 /

+0.8 (+10.72%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
XNCR Xencor
$30.08 /

+1.64 (+5.77%)

OCUL Ocular Therapeutix
$8.26 /

+0.8 (+10.72%)

MGTA Magenta Therapeutics
$9.22 /

+0.14 (+1.54%)

BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

XNCR Xencor
$30.08 /

+1.64 (+5.77%)

OCUL Ocular Therapeutix
$8.26 /

+0.8 (+10.72%)

MGTA Magenta Therapeutics
$9.22 /

+0.14 (+1.54%)

BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.